Cilostamide produces hyperpolarization associated with katp channel activation, but does not augment endothelium-derived hyperpolarization in rat mesenteric arteries

Yasuo Kansui, Kenichi Goto, Koji Fujii, Hideyuki Oniki, Kiyoshi Matsumura, Mitsuo Iida

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Non-nitric oxide/prostaglandin-mediated endothelium-derived hyperpolarization (EDH) is considered to be mediated, in part, by gap junctions and it has been suggested that cAMP increases endothelium-derived hyperpolarizing factor (EDHF)-mediated relaxation through the modulation of gap junctions. Cilostamide, which inhibits phosphodiesterase III, has been suggested to augment EDHF-type relaxation by increasing the concentration of cAMP. In the present study, we investigated the effect of cilostamide on EDH per se in mesenteric arteries of Wistar rats using a conventional microelectrode technique. The resting membrane potential of the mesenteric arteries was significantly more negative in the presence of 10-6 mol/L cilostamide compared with control conditions. Furthermore, EDH in response to 10 -6 mol/L acetylcholine (ACh) in the presence of 10-5 mol/L indomethacin and 10-4 mol/L NG-nitro-L-arginine was decreased in the presence of 10-6 mol/L cilostamide by approximately 5 and 3.5 mV in proximal and distal arteries, respectively. Glibenclamide (10-5 mol/L), an ATP-sensitive potassium channel (KATP) inhibitor, abolished the hyperpolarization to 10-6 mol/L cilostamide. Furthermore, in the presence of glibenclamide, ACh-induced EDH was unaffected by cilostamide, suggesting that the inhibition of ACh-induced hyperpolarization by cilostamide in the absence of glibenclamide may be due to the smaller driving force for hyperpolarization because of the more negative membrane potential under such conditions. The findings of the present study suggest that cilostamide produces hyperpolarization by activating KATP channels, presumably by increasing cAMP. However, cilostamide alone may not directly affect EDH.

元の言語英語
ページ(範囲)729-733
ページ数5
ジャーナルClinical and Experimental Pharmacology and Physiology
36
発行部数7
DOI
出版物ステータス出版済み - 7 1 2009

Fingerprint

Mesenteric Arteries
Endothelium
Glyburide
Acetylcholine
KATP Channels
Gap Junctions
Membrane Potentials
Type 3 Cyclic Nucleotide Phosphodiesterases
cilostamide
Nitroarginine
Microelectrodes
Indomethacin
Oxides
Prostaglandins
Wistar Rats
Arteries

All Science Journal Classification (ASJC) codes

  • Physiology
  • Pharmacology
  • Physiology (medical)

これを引用

Cilostamide produces hyperpolarization associated with katp channel activation, but does not augment endothelium-derived hyperpolarization in rat mesenteric arteries. / Kansui, Yasuo; Goto, Kenichi; Fujii, Koji; Oniki, Hideyuki; Matsumura, Kiyoshi; Iida, Mitsuo.

:: Clinical and Experimental Pharmacology and Physiology, 巻 36, 番号 7, 01.07.2009, p. 729-733.

研究成果: ジャーナルへの寄稿記事

@article{8957d93a50b341cab9a4d3fd699892c2,
title = "Cilostamide produces hyperpolarization associated with katp channel activation, but does not augment endothelium-derived hyperpolarization in rat mesenteric arteries",
abstract = "Non-nitric oxide/prostaglandin-mediated endothelium-derived hyperpolarization (EDH) is considered to be mediated, in part, by gap junctions and it has been suggested that cAMP increases endothelium-derived hyperpolarizing factor (EDHF)-mediated relaxation through the modulation of gap junctions. Cilostamide, which inhibits phosphodiesterase III, has been suggested to augment EDHF-type relaxation by increasing the concentration of cAMP. In the present study, we investigated the effect of cilostamide on EDH per se in mesenteric arteries of Wistar rats using a conventional microelectrode technique. The resting membrane potential of the mesenteric arteries was significantly more negative in the presence of 10-6 mol/L cilostamide compared with control conditions. Furthermore, EDH in response to 10 -6 mol/L acetylcholine (ACh) in the presence of 10-5 mol/L indomethacin and 10-4 mol/L NG-nitro-L-arginine was decreased in the presence of 10-6 mol/L cilostamide by approximately 5 and 3.5 mV in proximal and distal arteries, respectively. Glibenclamide (10-5 mol/L), an ATP-sensitive potassium channel (KATP) inhibitor, abolished the hyperpolarization to 10-6 mol/L cilostamide. Furthermore, in the presence of glibenclamide, ACh-induced EDH was unaffected by cilostamide, suggesting that the inhibition of ACh-induced hyperpolarization by cilostamide in the absence of glibenclamide may be due to the smaller driving force for hyperpolarization because of the more negative membrane potential under such conditions. The findings of the present study suggest that cilostamide produces hyperpolarization by activating KATP channels, presumably by increasing cAMP. However, cilostamide alone may not directly affect EDH.",
author = "Yasuo Kansui and Kenichi Goto and Koji Fujii and Hideyuki Oniki and Kiyoshi Matsumura and Mitsuo Iida",
year = "2009",
month = "7",
day = "1",
doi = "10.1111/j.1440-1681.2009.05142.x",
language = "English",
volume = "36",
pages = "729--733",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Cilostamide produces hyperpolarization associated with katp channel activation, but does not augment endothelium-derived hyperpolarization in rat mesenteric arteries

AU - Kansui, Yasuo

AU - Goto, Kenichi

AU - Fujii, Koji

AU - Oniki, Hideyuki

AU - Matsumura, Kiyoshi

AU - Iida, Mitsuo

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Non-nitric oxide/prostaglandin-mediated endothelium-derived hyperpolarization (EDH) is considered to be mediated, in part, by gap junctions and it has been suggested that cAMP increases endothelium-derived hyperpolarizing factor (EDHF)-mediated relaxation through the modulation of gap junctions. Cilostamide, which inhibits phosphodiesterase III, has been suggested to augment EDHF-type relaxation by increasing the concentration of cAMP. In the present study, we investigated the effect of cilostamide on EDH per se in mesenteric arteries of Wistar rats using a conventional microelectrode technique. The resting membrane potential of the mesenteric arteries was significantly more negative in the presence of 10-6 mol/L cilostamide compared with control conditions. Furthermore, EDH in response to 10 -6 mol/L acetylcholine (ACh) in the presence of 10-5 mol/L indomethacin and 10-4 mol/L NG-nitro-L-arginine was decreased in the presence of 10-6 mol/L cilostamide by approximately 5 and 3.5 mV in proximal and distal arteries, respectively. Glibenclamide (10-5 mol/L), an ATP-sensitive potassium channel (KATP) inhibitor, abolished the hyperpolarization to 10-6 mol/L cilostamide. Furthermore, in the presence of glibenclamide, ACh-induced EDH was unaffected by cilostamide, suggesting that the inhibition of ACh-induced hyperpolarization by cilostamide in the absence of glibenclamide may be due to the smaller driving force for hyperpolarization because of the more negative membrane potential under such conditions. The findings of the present study suggest that cilostamide produces hyperpolarization by activating KATP channels, presumably by increasing cAMP. However, cilostamide alone may not directly affect EDH.

AB - Non-nitric oxide/prostaglandin-mediated endothelium-derived hyperpolarization (EDH) is considered to be mediated, in part, by gap junctions and it has been suggested that cAMP increases endothelium-derived hyperpolarizing factor (EDHF)-mediated relaxation through the modulation of gap junctions. Cilostamide, which inhibits phosphodiesterase III, has been suggested to augment EDHF-type relaxation by increasing the concentration of cAMP. In the present study, we investigated the effect of cilostamide on EDH per se in mesenteric arteries of Wistar rats using a conventional microelectrode technique. The resting membrane potential of the mesenteric arteries was significantly more negative in the presence of 10-6 mol/L cilostamide compared with control conditions. Furthermore, EDH in response to 10 -6 mol/L acetylcholine (ACh) in the presence of 10-5 mol/L indomethacin and 10-4 mol/L NG-nitro-L-arginine was decreased in the presence of 10-6 mol/L cilostamide by approximately 5 and 3.5 mV in proximal and distal arteries, respectively. Glibenclamide (10-5 mol/L), an ATP-sensitive potassium channel (KATP) inhibitor, abolished the hyperpolarization to 10-6 mol/L cilostamide. Furthermore, in the presence of glibenclamide, ACh-induced EDH was unaffected by cilostamide, suggesting that the inhibition of ACh-induced hyperpolarization by cilostamide in the absence of glibenclamide may be due to the smaller driving force for hyperpolarization because of the more negative membrane potential under such conditions. The findings of the present study suggest that cilostamide produces hyperpolarization by activating KATP channels, presumably by increasing cAMP. However, cilostamide alone may not directly affect EDH.

UR - http://www.scopus.com/inward/record.url?scp=67650742382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650742382&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1681.2009.05142.x

DO - 10.1111/j.1440-1681.2009.05142.x

M3 - Article

C2 - 19207721

AN - SCOPUS:67650742382

VL - 36

SP - 729

EP - 733

JO - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - 7

ER -